HKUMed identifies PLK4 as a promising therapeutic target for TP53 mutated AML, demonstrated in Queen Mary Hospital and other studies

HKUMed identifies PLK4 as a promising therapeutic target for TP53 mutated AML, demonstrated in Queen Mary Hospital and other studies

* This article was originally published here

Post a Comment

Previous Post Next Post